Hong Kong and Queensland collaborating on vaccine for nasopharyngeal cancer

Doctors seek funding in HK for more clinical trials.

Delegates from the Queensland Institute of Medical Research are in Hong Kong this week to attract investment in more clinical trials for its promising vaccine for nasopharyngeal cancer. They will also brief existing philanthropic supporters on the research project’s progress.

The project is an important collaboration between Hong Kong University and QIMR with a goal of improving cancer survival for people with nasopharyngeal carcinoma, an aggressive cancer and major health problem in South East Asia.

The long term aim of the research is to develop a vaccine that prevents nasopharyngeal cancer.

Queensland Treasurer and Minister for Trade Tim Nicholls extended an invitation to Hong Kong-based CK Life Sciences to lead a biotechnology delegation to Brisbane in October as part of 2013 AusBiotech.

He also congratulated researchers on the project’s success and said its continuation presented an exciting, new opportunity for potential investors.